Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Once-yearly zoledronate—an effective preventative therapy for new fractures after hip fracture?

Nature Clinical Practice Endocrinology & Metabolism volume 4, pages 308–309 (2008)Cite this article

boxed-textLyles KW et al. (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357: 1799–1809

Administration of intravenous zoledronate after hip fracture causes reductions of about 30% in both recurrent fracture rates and mortality, without significant adverse effects

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Black DM et al. (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356: 1809–1822

    Article  CAS  PubMed  Google Scholar 

  2. McClung MR et al. (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344: 333–340

    Article  CAS  PubMed  Google Scholar 

  3. Colón-Emeric C et al. (2003) The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos Int 14: 879–883

    Article  PubMed  Google Scholar 

  4. Rosen CJ and Brown S (2003) Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N Engl J Med 348: 1503–1504

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand i.reid@auckland.ac.nz

Authors and Affiliations

  1. IR Reid is a Professor of Medicine and Endocrinology in the Faculty of Medical and Health Sciences, University of Auckland, New Zealand.,

    Ian R Reid

Authors
  1. Ian R Reid
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author has declared associations with the following companies: Amgen, Eli Lilly, Merck, Novartis, Procter and Gamble, and Roche. See the article online for full details of the relationships.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reid, I. Once-yearly zoledronate—an effective preventative therapy for new fractures after hip fracture?. Nat Rev Endocrinol 4, 308–309 (2008). https://doi.org/10.1038/ncpendmet0813

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0813

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing